The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Long-term benefit (LTB) of sunitinib (SU) treatment for metastatic renal cell carcinoma (mRCC): Retrospective analysis for clinical biomarkers identification.
Oren Smaletz
Consultant or Advisory Role - Pfizer
Honoraria - Bayer; Pfizer
Research Funding - Bayer; Novartis; Pfizer; Roche
Matias Chacon
No relevant relationships to disclose
Ludmila de Oliveira Koch
No relevant relationships to disclose
Daniela Regina de Carvalho Rocha
No relevant relationships to disclose
Fernanda Camila Cardoso
No relevant relationships to disclose